ICER releases draft evidence report on aducanumab for Alzheimer’s disease

ICER

5 May 2021 - Given the risk of side effects and the uncertainty of benefit, ICER assigns a draft rating of “insufficient” to the strength of evidence on whether aducanumab provides a net health benefit for patients.

The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of aducanumab (Biogen) for the treatment of Alzheimer’s disease. An FDA decision on aducanumab is expected in June. 

This preliminary draft marks the midpoint of ICER’s iterative process of assessing the evidence on aducanumab, and these findings should not be interpreted to be ICER’s final conclusions.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder